Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
Form 4 filing overview for Agios Pharmaceuticals (AGIO)
Director Dr. David Scadden reported multiple equity transactions dated 18-20 June 2025. The filing shows:
- Table I – Common stock: On 20 June 2025, Scadden acquired 2,120 shares of common stock through a Rule 16b-3 “M” transaction (settlement of previously granted RSUs). Post-transaction direct ownership stands at 17,603 shares.
- Table II – New equity awards (18 June 2025):
- RSUs: 2,816 restricted stock units, each convertible into one share, vesting in full on 18 Jun 2026.
- Stock options: 15,768 options with a $35.50 exercise price, vesting 100 % on 18 Jun 2026 and expiring 18 Jun 2035.
- Derivative settlement (20 June 2025): The earlier 2,120 RSUs granted 20 Jun 2024 were settled for an equal number of common shares; no derivative balance remains.
No sale of common shares occurred, and all holdings are disclosed as directly owned. These awards reflect routine director compensation and do not, by themselves, signify a change in corporate strategy or financial outlook.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 insider activity
Director Cynthia Smith reported several equity transactions dated 18-20 June 2025. In the non-derivative table, Smith acquired 2,120 common shares (code M, price $0) as previously granted restricted stock units (RSUs) vested. After the transaction her direct beneficial ownership increased to 10,112 common shares.
In the derivative section, the board member accepted new equity awards as part of 2025 director compensation: (i) 2,816 RSUs that vest 100 % on 18 June 2026, and (ii) 15,768 stock options exercisable at $35.50 per share with the same one-year cliff vesting and a 10-year expiration (18 June 2035). A previously outstanding 2024 RSU grant (2,120 units) was marked as fully converted (code M) and now shows zero derivative balance. No dispositions or open-market sales were disclosed, and all securities remain held directly by Smith.
The filing signals alignment between the director and shareholders through increased equity ownership and fresh option incentives. However, the modest absolute share count limits immediate valuation impact. No earnings figures, business updates, or material corporate events were included in this filing.
Agios Pharmaceuticals, Inc. (AGIO) filed a Form S-8 on 18 June 2025 to register additional shares under its 2023 Stock Incentive Plan, as amended. The filing is purely administrative and incorporates by reference the prior S-8 (File No. 333-272615, filed 13 June 2023), with the only new content being updated exhibits and signatures.
The registration enables the continued issuance of equity-based compensation to employees, directors and consultants. Exhibits include the company’s Restated Certificate of Incorporation, current By-laws, the updated plan document, the legal opinion of Wilmer Cutler Pickering Hale and Dorr LLP, the PwC consent, and filing-fee calculations. No financial statements, earnings data or transactional details are provided.
Because Form S-8 does not itself issue shares but merely registers them for potential future grants, there is no immediate cash impact. However, any subsequent grants will add to the company’s share count and could modestly dilute existing shareholders.